# XPO5 regulates ferroptosis via MITF-ACSL4 signaling to drive CRPC progression and serves as a druggable target

Source: [cell.com](https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00586-0?rss=yes) · 2026-11-12 · Medicine
Page: https://themorning.science/story/xpo5-regulates-ferroptosis-via-mitf-acsl4-signaling-to-drive-crpc-progression-an-ecfdc9b3478fa83e
Kind: research · Impact: low

## In brief

- Study by Wang et al. reports that XPO5 promotes castration-resistant prostate cancer (CRPC) progression by suppressing ferroptosis via the MITF-ACSL4 axis.
- The authors identify an XPO5-targeting molecular glue degrader that induces ferroptosis in cellular, CDX and PDX models.
- The findings are preclinical and the authors describe XPO5 as a potential druggable target.

## Why it matters

It identifies a mechanistic link between a nuclear export protein, ferroptosis suppression and CRPC progression, and tests a degrader in several tumour models, which could guide future drug development. Results remain preclinical.

## Timeline

- 2026-11-12: Study published in Cell Reports Medicine

## Coverage

- [XPO5 regulates ferroptosis via MITF-ACSL4 signaling to drive CRPC progression and serves as a druggable target](https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00586-0?rss=yes) — cell.com, 2026-11-12

Tags: prostate cancer, ferroptosis, xpo5, protein degradation, drug target

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science